FDA Clears Darunavir (Prezista) for Pregnant Women With HIV FDA Clears Darunavir (Prezista) for Pregnant Women With HIV
Data show darunavir, when taken with ritonavir, is safe, well tolerated, and effective during pregnancy and the postpartum period. < br / > < i > FDA Approvals < /i > (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 21, 2016 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news
FDA Clears Darunavir (Prezista) for Pregnant Women With HIVFDA Clears Darunavir (Prezista) for Pregnant Women With HIV
Data show darunavir, when taken with ritonavir, is safe, well tolerated, and effective during pregnancy and the postpartum period. FDA Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - July 21, 2016 Category: Drugs & Pharmacology Tags: HIV/AIDS News Alert Source Type: news
U.S. FDA Approves Prezista (darunavir) for Use in Pregnant Women with HIV
TITUSVILLE, N.J., July 18, 2016 /PRNewswire/ -- Janssen Therapeutics, Division of Janssen Products, LP (Janssen), today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion to the Prezista (darunavir) U.S. Prescribing... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 18, 2016 Category: Drugs & Pharmacology Source Type: news
Prezista (Darunavir) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 30, 2016 Category: Drugs & Pharmacology Source Type: news
Darunavir Plus Cobicistat Works Well in Older HIV Groups (CME/CE)
(MedPage Today) -- Agent to boost protease inhibitor drugs seems safe, effective in older patients (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - June 22, 2016 Category: Infectious Diseases Source Type: news
NRTI Sparing Therapy in Virologically Controlled HIVNRTI Sparing Therapy in Virologically Controlled HIV
This study explores the combination of rilpivirine plus boosted darunavir as an option when switching from standard cART in patients who are virologically suppressed. JAIDS: Journal of Acquired Immune Deficiency Syndromes (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - June 1, 2016 Category: Infectious Diseases Tags: HIV/AIDS Journal Article Source Type: news
Comunicado de la FDA sobre la seguridad de los medicamentos: Importantes interacciones entre el medicamento Victrelis (boceprevir) y los medicamentos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir
El 8 de febrero del 2012, la Administración de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) notificó a los profesionales de la salud y a los pacientes que la interacción entre Victrelis (boceprevir), un medicamento inhibidor de la proteasa del virus de hepatitis C (VHC), y ciertos inhibidores de la proteasa del virus de inmunodeficiencia humana (VIH) reforzados con ritonavir (atazanavir, lopinavir, darunavir) tiene el potencial de reducir la eficacia de dichos medicamentos cuando se usan conjuntamente (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - March 4, 2016 Category: Drugs & Pharmacology Source Type: news
Prezcobix (Darunavir and Cobicistat Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - March 4, 2016 Category: Drugs & Pharmacology Source Type: news
Janssen Embraces Continuous Manufacturing for Prezista
Strategy seeks CM’s well-researched savings and efficiencies for its Gurabo, Puerto Rico, plant (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - October 8, 2015 Category: Pharmaceuticals Source Type: news
Darunavir and Trimethoprim-Sulfamethoxazole Cross-ReactivityDarunavir and Trimethoprim-Sulfamethoxazole Cross-Reactivity
This study examines the cross-reactivity between both drugs. AIDS (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 25, 2015 Category: Consumer Health News Tags: HIV/AIDS Journal Article Source Type: news
Prezcobix™ (darunavir / cobicistat) for the Treatment of HIV-1
Prezcobix™ (darunavir / cobicistat), discovered and developed by Janssen Therapeutics, is a fixed-dose antiretroviral combination tablet indicated for the treatment of human immunodeficiency virus (HIV-1) infection. (Source: Drug Development Technology)
Source: Drug Development Technology - May 13, 2015 Category: Pharmaceuticals Source Type: news
Africa: Johnson & Johnson Expands Ip Policy to Create Broad Access in 128 Countries for Development of New and Optimized HIV Medicine Formulations for Children Living With HIV
[PR Newswire] Raritan, New Jersey -Expanded Policy will Increase Access for Darunavir Pediatric Formulations in 128 Resource-Limited Countries (Source: AllAfrica News: HIV-Aids and STDs)
Source: AllAfrica News: HIV-Aids and STDs - May 12, 2015 Category: Infectious Diseases Source Type: news
Dolutegravir Remains Superior to Boosted Darunavir for HIV-1Dolutegravir Remains Superior to Boosted Darunavir for HIV-1
Once-daily dolutegravir maintains its higher virological response rates over those of ritonavir-boosted darunavir in treatment-naïve adults with HIV-1 infection, according to 96-week results from the FLAMINGO study. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 6, 2015 Category: Consumer Health News Tags: HIV/AIDS News Source Type: news
Darunavir/Cobicistat (Prezcobix) Combo Pill Clears FDADarunavir/Cobicistat (Prezcobix) Combo Pill Clears FDA
The fixed-dose combination of the antiretroviral drug darunavir (800 mg) and the pharmacokinetic enhancer cobicistat (150 mg) is for adults with HIV-1 infection and no darunavir resistance mutations. FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 30, 2015 Category: Consumer Health News Tags: HIV/AIDS News Alert Source Type: news
FDA Approves Two Medications to Treat HIV Infection: Evotaz and Prezcobix
On January 29, 2015, FDA sent e-mails noting the approval of two HIV medications to treat HIV infection:
"On January 29, 2015, FDA approved Evotaz, a fixed dose combination tablet containing 300 mg of atazanavir and 150 mg of cobicistat. Evotaz is indicated in combination with other antiretroviral agents for the treatment of … human immunodeficiency virus (HIV 1) infection in adults."
"On January 29, 2015, FDA approved Prezcobix a fixed dose combination tablet containing 800 mg of darunavir and 150 mg of cobicistat.
"Prezcobix is indicated in combination with other antiretroviral agents for the ...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - January 30, 2015 Category: Infectious Diseases Source Type: news
